These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 24999839)

  • 1. Determinants in V2C2 region of HIV-1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context-dependent manner.
    Patil S; Choudhary I; Chaudhary NK; Ringe R; Bansal M; Shukla BN; Boliar S; Chakrabarti BK; Bhattacharya J
    Virology; 2014 Aug; 462-463():266-72. PubMed ID: 24999839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection.
    Ringe R; Thakar M; Bhattacharya J
    Retrovirology; 2010 Sep; 7():76. PubMed ID: 20860805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies.
    Ringe R; Phogat S; Bhattacharya J
    Virology; 2012 Apr; 426(1):34-41. PubMed ID: 22314018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies.
    Deshpande S; Patil S; Kumar R; Shrivastava T; Srikrishnan AK; Murugavel KG; Koff WC; Chakrabarti BK; Bhattacharya J
    Retrovirology; 2016 Jun; 13(1):41. PubMed ID: 27307004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes.
    Das S; Boliar S; Mitra N; Samal S; Bansal M; Koff WC; Chakrabarti BK
    Retrovirology; 2016 Nov; 13(1):81. PubMed ID: 27871328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
    Utachee P; Isarangkura-na-ayuthaya P; Tokunaga K; Ikuta K; Takeda N; Kameoka M
    Retrovirology; 2014 Apr; 11():32. PubMed ID: 24758333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three amino acid residues in the envelope of human immunodeficiency virus type 1 CRF07_BC regulate viral neutralization susceptibility to the human monoclonal neutralizing antibody IgG1b12.
    Nie J; Zhao J; Chen Q; Huang W; Wang Y
    Virol Sin; 2014 Oct; 29(5):299-307. PubMed ID: 25273335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes.
    Hoffenberg S; Powell R; Carpov A; Wagner D; Wilson A; Kosakovsky Pond S; Lindsay R; Arendt H; Destefano J; Phogat S; Poignard P; Fling SP; Simek M; Labranche C; Montefiori D; Wrin T; Phung P; Burton D; Koff W; King CR; Parks CL; Caulfield MJ
    J Virol; 2013 May; 87(10):5372-83. PubMed ID: 23468492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain.
    Utachee P; Nakamura S; Isarangkura-Na-Ayuthaya P; Tokunaga K; Sawanpanyalert P; Ikuta K; Auwanit W; Kameoka M
    J Virol; 2010 May; 84(9):4311-20. PubMed ID: 20164234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naturally occurring substitutions of conserved residues in human immunodeficiency virus type 1 variants of different clades are involved in PG9 and PG16 resistance to neutralization.
    Thenin S; Roch E; Samleerat T; Moreau T; Chaillon A; Moreau A; Barin F; Braibant M
    J Gen Virol; 2012 Jul; 93(Pt 7):1495-1505. PubMed ID: 22492917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure.
    Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; Nanlohy NM; van Baarle D; van Nuenen AC; Hessell AJ; Schuitemaker H
    J Gen Virol; 2010 May; 91(Pt 5):1354-64. PubMed ID: 20053822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
    Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
    Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
    J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups.
    Braibant M; Gong EY; Plantier JC; Moreau T; Alessandri E; Simon F; Barin F
    AIDS; 2013 May; 27(8):1239-44. PubMed ID: 23343910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
    Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
    Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
    Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.
    Sharma VA; Kan E; Sun Y; Lian Y; Cisto J; Frasca V; Hilt S; Stamatatos L; Donnelly JJ; Ulmer JB; Barnett SW; Srivastava IK
    Virology; 2006 Aug; 352(1):131-44. PubMed ID: 21894641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope.
    Dacheux L; Moreau A; Ataman-Onal Y; Biron F; Verrier B; Barin F
    J Virol; 2004 Nov; 78(22):12625-37. PubMed ID: 15507649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B.
    Xu W; Smith-Franklin BA; Li PL; Wood C; He J; Du Q; Bhat GJ; Kankasa C; Katinger H; Cavacini LA; Posner MR; Burton DR; Chou TC; Ruprecht RM
    J Hum Virol; 2001; 4(2):55-61. PubMed ID: 11437315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B.
    Kitabwalla M; Ferrantelli F; Wang T; Chalmers A; Katinger H; Stiegler G; Cavacini LA; Chou TC; Ruprecht RM
    AIDS Res Hum Retroviruses; 2003 Feb; 19(2):125-31. PubMed ID: 12639248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.